Morepen Laboratories Ltd

MOREPENLAB | 500288

₹80.25

+0.83 (1.05%)

Trade now

Performance

Historical price movement and trading activity

Trading Data

Today's High82.89

Today's Low78.92

Open80.3

Previous Close80.25

Volume36485619

Total Traded Value High2952970779.21

Overview

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre. Morepen Laboratories Limited was established in 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride. During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT. During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products. During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule. During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S. During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'. During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment. In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023. During the year 2024, new capacities were built for manufacture of tablets wherein tablet manufacture capacity were increased to 162 units from 92.40 units in 2022-23. The capacities for capsule, oral liquid, sachet and dry syrup has also be enhanced in FY24. The Company has developed / commercialized various new products such as Sitagliptin Hydrochloride (Anti-diabetic), Finerenone (chronic kidney disease), Cariprazine HCl (Atypical Anti-Psychotic), Resmetirom (for NASH), Bempedoic Acid (Anti-Hypercholesterolemic) & Rupatadine Fumarte (Anti-histaminic) during the year 2024-25. The newly developing molecules comprising of Sitagliptin (Anti-diabetic), Linagliptin (Anti-diabetic), Edoxaban (Anti-coagulant), and Empagliflozin (Anti-diabetic), and others, achieved a remarkable revenue growth of over 46%, further strengthening API revenue position. The Company commenced production of orthopaedic products, marking its entry into a new and promising therapeutic segment in 2025. Morepen Medipath Limited was incorporated in January 2025. Company has achieved a leadership position as one of the largest suppliers of the anti-asthmatic drug, Montelukast Sodium, produced at its USFDA-approved Masulkhana facility in 2025.

Sector & Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Listing Exchange

National Stock Exchange (NSE)

Bombay Stock Exchange (BSE)

Fundamentals

Financial strength and ownership structure

Valuation & Ratios

Market Capitalisation₹2,621.96

Price to Book (PB)2.27

Price to Earnings (PE)22.26

Return on Equity (ROE)11.78%

Earnings Per Share (EPS)2.15

Dividend Yield0.42%

Financial Performance

421.77

444.55

423.07

455.22

437.73

452.78

465.85

425.24

411.58

484.16

484.72

570.13

Sep

'23

Dec

'23

Mar

'24

Jun

'24

Sep

'24

Dec

'24

Mar

'25

Jun

'25

Sep

'25

Dec

'25

Mar

'26

Jun

'26

Shareholding Pattern

35.65%

Sep

'25

Dec

'25

Mar

'26

Jun

'26

Technicals

Price-based indicators and levels

Indicators

INDICATORVALUESIGNAL

Relative Strength
Index (RSI)+79.53Overbought

MACD+5.02Bullish

Support and Resistance Levels

R391.97

R287.73

R183.58

S175.19

S270.95

S366.80

Moving Averages

PERIODSMAEMA

20D Moving Average61.3563.39

50D Moving Average55.9657.09

200D Moving Average45.1249.90

News

Hot Pursuit

Morepen Laboratories Ltd leads gainers in 'A' group

23 Feb 2026

Blue Jet Healthcare Ltd, BLS International Services Ltd, CIE Automotive India Ltd and Kitex Garments Ltd are among the other gainers in the BSE's 'A' group today, 23 February 2026.

Blue Jet Healthcare Ltd, BLS International Services Ltd, CIE Automotive India Ltd and Kitex Garments Ltd are among the other gainers in the BSE's 'A' group today, 23 February 2026. Morepen Laboratories Ltd surged 15.01% to Rs 45.21 at 11:45 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 46.1 lakh shares were traded on the counter so far as against the average daily volumes of 1.4 lakh shares in the past one month. Blue Jet Healthcare Ltd soared 9.95% to Rs 390.8. The stock was the second biggest gainer in 'A' group. On the BSE, 88032 shares were traded on the counter so far as against the average daily volumes of 31068 shares in the past one month. BLS International Services Ltd spiked 8.23% to Rs 290.65. The stock was the third biggest gainer in 'A' group. On the BSE, 13.23 lakh shares were traded on the counter so far as against the average daily volumes of 5.42 lakh shares in the past one month. CIE Automotive India Ltd exploded 7.07% to Rs 502.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.5 lakh shares were traded on the counter so far as against the average daily volumes of 15656 shares in the past one month. Kitex Garments Ltd added 6.15% to Rs 197.55. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.24 lakh shares were traded on the counter so far as against the average daily volumes of 2.48 lakh shares in the past one month. Powered by Capital Market - Live News

Morepen Labs surges after bagging Rs 825 crore CDMO contract from global pharma firm

23 Feb 2026

Morepen Laboratories zoomed 13.38% to Rs 44.57 after the company announced that it has secured a multi-year contract development and manufacturing organization (CDMO) mandate valued at approximately Rs 825 crore from a leading global pharma major.

The company stated that the supplies under the said mandate are expected to commence within the next 4'5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. Morepen Labs further said that this engagement marks one of the most significant single CDMO mandates in the Company's history, as it scales its global manufacturing footprint. Sushil Suri, chairman & managing director, said: This mandate represents an important milestone in the evolution of Morepen's manufacturing platform. We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses. Morepen Laboratories is a vertically integrated pharmaceutical and healthcare company delivering APIs, branded generics, medical devices, and consumer wellness products worldwide. The company's consolidated net profit rose 3.07% to Rs 27.51 crore on a 6.93% increase in revenue to Rs 484.16 crore in Q3 FY26 as compared with Q3 FY25. On the BSE, over 20.92 lakh shares of the company had changed hands at the counter as compared with the average trading volume of 1.56 lakh shares. In the last one year, the scrip has lost 12.08% while the benchmark S&P BSE Sesnex and the S&P BSE Healthcare index have gained 11.90% and 9.85%, respectively. Powered by Capital Market - Live News

Corporate News

Morepen Laboratories subsidiary Morepen RX allotted shares totaling Rs 20 crore through a rights issue

6 Aug 2026

Morepen Laboratories Limited announced that its wholly owned subsidiary, Morepen RX Limited (MRX), has allotted 20,00,00,000 equity shares with a face value of Rs 10 each, totaling Rs 20,00,00,000, to the company through a rights issue. Consequently, Morepen Laboratories Limited’s shareholding in MRX has increased to 2,70,82,356 equity shares, and MRX continues to be a wholly owned subsidiary. MRX, incorporated on March 17, 2023, had a turnover of Rs 5,449.84 lakh and a net worth of Rs 47.72 lakh based on audited financial statements for the financial year ended March 31, 2026.

Morepen Laboratories utilized Rs 88.83 crore, extending project timelines to March 2027

4 Aug 2026

A Monitoring Agency report indicates mixed progress for Morepen Laboratories Limited regarding the utilization of funds raised through an issuance. While the company has largely deployed the Rs 88.83 crore initially planned for completion by March 31, 2025, and the Rs 33.97 crore slated for March 31, 2026, timelines have been extended to March 31, 2026, and March 31, 2027, respectively, raising concerns about project planning and execution. The report notes a Rs 4.55 crore transfer to the company’s current account and a remaining balance of Rs 0.09 crore, prompting a review of vendor billing processes. Despite these delays, the company has effectively utilized funds for working capital and made prudent short-term investments, and the report acknowledges flexibility in fund deployment. The agency recommends strengthening project management, improving internal oversight, and enhancing transparency with investors.

Morepen Laboratories reports record Rs 575.31 crore quarterly revenue, CDMO mandate commercializing

4 Aug 2026

Morepen Laboratories Limited announced its highest-ever quarterly revenue of Rs 575.31 crore and earnings for the quarter ended June 30, 2026, alongside a 207% increase in EBITDA and a 394% rise in profit after tax. The company’s CDMO mandate, valued at Rs 825 crore, has entered full-scale commercialization, with Rs 58 crore in commercial dispatches completed during the quarter, supported by a 31% growth in the API business and 19% growth in the medical devices business.

Morepen Laboratories to conduct board meeting

29 Jul 2026

On 4 August 2026

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Morepen Laboratories commences commercial supplies under its Rs 825 cr CDMO mandate

1 Jul 2026

Morepen Laboratories today issued an update on its recently announced Rs 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage. Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately Rs 225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements. The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.

Board of Morepen Laboratories recommends final dividend

27 May 2026

Of Rs 0.2 per share

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Morepen Laboratories revises board meeting date

22 May 2026

To 26 May 2026

Morepen Laboratories has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 26 May 2026.

Morepen Laboratories schedules board meeting

16 May 2026

On 22 May 2026

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Morepen Laboratories' Masulakhanna facility clears USFDA inspection

17 Apr 2026

Morepen Laboratories announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its Masulakhanna (HP) facility, with Zero observations (NIL Form 483). This marks the Fourth consecutive NIL 483 inspection for Morepen over the past eight years, underscoring the Company's unwavering commitment to global quality and regulatory standards.

Morepen Laboratories repays bank facilities worth Rs 79 cr

11 Mar 2026

Morepen Laboratories has repaid working capital demand loan facility and cash credit limit availed from Kotak Mahindra Bank amounting to Rs 79 crore on 02 March 2026. Powered by Capital Market - Live News

Morepen Lab secures multi-year order of Rs 825 cr under CDMO segment

23 Feb 2026

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharma major. Supplies under the mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. Powered by Capital Market - Live News

Results - Announcements

Morepen Laboratories Ltd consolidated sales up 17.62% on year in Q2FY2026, net profit jumped 258.92%

4 Aug 2026

Morepen Laboratories Ltd share price ticked higher by 1.19% to Rs 57.68 after the company's net profit soared by 258.92% to Rs 56.35 crore, while revenue from operations gained 17.62% to Rs 570.13 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 5.95%. It has improved by 1.51% over last one week and advanced by 11.59% in last one month while the market capitalization of Morepen Laboratories Ltd has marginally improved by 4.32% and 32.41% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 74.53 crore in Q2 FY26, jumping 380.22% year-on-year, and surging by 220.01% quarter-on-quarter. EBITDA came in at Rs 77 crore, rallying 291.30% YoY and expanding by 383.80% sequentially. Total expenses inched up 6.42% to Rs 495.94 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 328.38 crore, increasing 13.01% YoY, while employee benefits expense was at Rs 62.44 crore, easing 6.26% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 7.17% to Rs 1811.58 crore, while net profit saw a strong growth of 22.15% to Rs 118.02 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 13917% to Rs 155.71 crore, and PBT registered a growth of 14.54% to Rs 155.11 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.06 crore in FY26, as against Rs 73.37 crore in FY25. Morepen Laboratories Ltd slipped 0.14% in last one year, outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Morepen Laboratories consolidated net profit declines 22.54% in the March 2026 quarter

27 May 2026

Sales rise 4.05% to Rs 484.72 crore

Net profit of Morepen Laboratories declined 22.54% to Rs 15.74 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales rose 4.05% to Rs 484.72 crore in the quarter ended March 2026 as against Rs 465.85 crore during the previous quarter ended March 2025. For the full year,net profit declined 19.61% to Rs 94.88 crore in the year ended March 2026 as against Rs 118.02 crore during the previous year ended March 2025. Sales declined 0.33% to Rs 1805.69 crore in the year ended March 2026 as against Rs 1811.58 crore during the previous year ended March 2025. Particulars Quarter Ended Year Ended Mar. 2026 Mar. 2025 % Var. Mar. 2026 Mar. 2025 % Var. Sales 484.72 465.85 4 1805.69 1811.58 0 OPM % 5.04 9.07 - 6.96 9.61 - PBDT 29.03 42.18 -31 130.52 184.09 -29 PBT 23.29 25.71 -9 94.09 155.11 -39 NP 15.74 20.32 -23 94.88 118.02 -20 Powered by Capital Market - Live News

Morepen Laboratories consolidated net profit rises 3.07% in the December 2025 quarter

14 Feb 2026

Sales rise 6.93% to Rs 484.16 crore

Net profit of Morepen Laboratories rose 3.07% to Rs 27.51 crore in the quarter ended December 2025 as against Rs 26.69 crore during the previous quarter ended December 2024. Sales rose 6.93% to Rs 484.16 crore in the quarter ended December 2025 as against Rs 452.78 crore during the previous quarter ended December 2024. Particulars Quarter Ended Dec. 2025 Dec. 2024 % Var. Sales 484.16 452.78 7 OPM % 9.57 7.98 - PBDT 45.80 40.14 14 PBT 35.42 35.21 1 NP 27.51 26.69 3 Powered by Capital Market - Live News

Insider Activity

Acquisitions

Liquid Holdings Private Limited

Promoter Group

Acquired 5000000 shares worth ₹12,50,00,000

Reported on 22 Sept 2022

Mode: Conversion of security

React Investments and Financial Services Private Limited

Promoter Group